Abstract:INTRODUCTIONGlioblastoma (GBM) is the most common malignant brain tumor in adults and has poor prognosis despite standard of care treatment. Nevertheless, certain patients surpass survival expectations. This study seeks to identify the clinical, molecular, and imaging characteristics of GBM associated with extended patient survival. METHODSIn this retrospective cohort study, we examined records of adult GBM patients (WHO 2016 classification) treated at Thomas Jefferson University Hospital from 2010 to 2023. Exclusion criteria included a preoperative Karnofsky Performance Status (KPS) below 60 and treatment with hypo-fractionated radiation therapy. Patients were categorized into two groups: short-term survivors (STS), who survived less than 36 months from diagnosis, and long-term survivors (LTS), who survived more than 36 months. We reviewed patient charts and pathology reports for comprehensive clinical and molecular data. For radiomics analysis, tumor segmentation was performed using CaPTk software on the initial diagnostic MRI (T1 pre and post-contrast, FLAIR and T2 sequences). The relationship between overall survival of more than three years was analyzed with univariable logistic models for potential predictors using R statistical software. RESULTSOf the cohort of 210 patients, 37 (17.6%) survived beyond three years. The median age at diagnosis was 55 years (range; 29-79) Twenty-two patients were male and 15 were female. Twenty-two percent had IDH mutation and 65% had MGMT methylation. Factors associated with long-term survival included younger age at diagnosis (p =0.007), MGMT hypermethylation (p =0.019), IDH mutation (p=0.001), absence of TERT mutation (p = 0.002), higher average number of adjuvant temozolomide cycles (10 vs. 5; p = 0.005), and smaller volume of enhancing tumor on T1 post-contrast imaging segmentation (p=0.022). But there was no significant difference in FLAIR abnormality or necrotic core volumes between the groups. CONCLUSIONIn our cohort of GBM patients, patients diagnosed at a younger age, MGMT hypermethylation, IDH mutation, absence of TERT mutation, receiving more cycles of adjuvant temozolomide treatment, and smaller enhancing tumor volume on preoperative T1 post-contrast imaging were associated with longer survival. Future research involving larger cohorts and validation of our findings is needed.

Mitochondrial DNA copy number as a prognostic marker is age-dependent in adult glioblastoma

High Copy Number of Mitochondrial Dna (mtdna) Predicts Good Prognosis in Glioma Patients

Gene Expression Analysis of Glioblastomas Identifies the Major Molecular Basis for the Prognostic Benefit of Younger Age.

High Leukocyte Mitochondrial DNA Content Contributes to Poor Prognosis in Glioma Patients Through Its Immunosuppressive Effect

Retrospective Clinical Trial Experimentally Validates Glioblastoma Genome-Wide Pattern of DNA Copy-Number Alterations Predictor of Survival.

Genetic Prognostic Factors in Adult Diffuse Gliomas: A 10-Year Experience at a Single Institution

Integrated Approach Reveals Role of Mitochondrial Germ-Line Mutation F18L in Respiratory Chain, Oxidative Alterations, Drug Sensitivity, and Patient Prognosis in Glioblastoma

Biomarker-based Prognostic Stratification of Young Adult Glioblastoma

Gene Expression Patterns Associated with Survival in Glioblastoma

Glioblastoma as an age-related neurological disorder in adults

Abstract 2234: Combined analysis of TERT, EGFR and IDH status define distinct prognostic classes of GBM

Mitochondrial Dna Copy Number in Whole Blood and Glioma Risk: A Case Control Study

Metabolic Modeling Identifies a Novel Molecular Type of Glioblastoma Associated with Good Prognosis.

Gene expression profiling and genetic markers in glioblastoma survival

Novel Prognostic Features and Personalized Treatment Strategies for Mitochondria-Related Genes in Glioma Patients

Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers

Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival.

Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas

Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma

New Molecular Prognostic Factors of Adult Diffuse Lower-Grade Gliomas in Post-2016 Molecular Era: a Retrospective Analysis from Single Center

Radt-38. Clinical, Molecular And Imaging Features Associated With Long Term Survival In Glioblastoma Patients